Analyst consensus rating
Benitec Biopharma Analyst Rating: Strong Buy
BNTC is rated Strong Buy by 6 analysts with a $24.17 target. As of 2026-08-20.
Direct answer
Benitec Biopharma's consensus rating is Strong Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.17.
Forecast evidence checked August 20, 2026.
Get free Benitec Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $12.75
- Average price target
- $24.17
- High price target
- $32.00
- Low price target
- $16.00
- Low target gap
- +25.5%
- Target upside
- +89.5%
- High target gap
- +151%
- Target range width
- 125.5%
- Consensus rating
- Strong Buy
- Analysts
- 6
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Benitec Biopharma?
Benitec Biopharma has a verified Strong Buy consensus. The same dataset has an average price target of $24.17.
How far are Benitec Biopharma's low and high targets from the recorded price?
The low target implies +25.5%, while the high target implies +151%.
How many analysts are included in Benitec Biopharma's consensus?
The verified consensus includes 6 analysts.
How is Benitec Biopharma's target upside or downside calculated?
The average target of $24.17 is divided by the recorded price of $12.75, then one is subtracted to produce +89.5%. This does not guarantee a future return.
When was Benitec Biopharma's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.